Patients with malignant diseases treated with cytotoxic chemotherapy are an important group of immunocompromised patients susceptible to opportunistic infections. Several reports document that diarrhoea in such patients may be associated with Clostridium difficile (Cudmore et al., 1982; Morris et al., 1984; Miller & Koornhof, 1984; Rampling et al., 1985; Heard et al., 1988) . The factors leadings to C. dificile infection in an individual patient are many, involving the frequent administration of antibacterial chemotherapy in such patients (Bartlett, 1979) , gastrointestinal toxicity of antineoplastic chemotherapy (Miller & Koornhof, 1984; Fainstein et al., 1981) , and possibly environmental exposure to the microorganism (Heard et al., 1988; Kim et al., 1981) . The clinical significance of treatment associated diarrhoea was evaluated in the homogenous cohort of patients with disseminated germ cell cancer requiring intensive chemotherapy, and C. difficile infection was found in a high proportion of such episodes.
Materials and methods
During a period of 24 months a prospective, consecutive study of the bacteriology of diarrhoea was done in patients with disseminated germ cell cancer treated with high-dose cisplatin, etoposide and bleomycin in cycles every 3rd week (Daugaard & R0rth, 1986) . The patients were treated in the same department throughout the study. Twenty-five patients were treated for a total of 90 series of chemotherapy (one patient died after two cycles of pneumococcal septicaemia, 15 patients had three cycles, six patients had four cycles, one patient had five cycles, one patient had six cycles and one patient had eight cycles). All patients received ketoconazole 200 mg daily from day six after chemotherapy and throughout the leukopenic phase (< 1.0 x 109 leukocytes/l). No prophylactic antibacterial therapy was given. During febrile episodes (>38.5°C rectally) while leukopenic, the patients were given empiric treatment with cefotaxime 2 g q 8 h or other agents according to microbiological findings. In 77% of the series the patients were leukopenic for a median of 6 days (range 1-16 days). In patients with diarrhoea faecal speci- symptoms for more than 4 weeks, and two patients had three episodes each. Distribution of C. difficile isolation throughout the study period was without identifiable clusters. The numbers of patients affected in the four half-year periods of the study were three, one, two and two with a total of six, two, three and three episodes of C. difficile associated diarrhoea, respectively.
The incidence of C. difficile isolation was 8% (2/25 patients) in the first cycle of chemotherapy, 12% (3/25 patients) in the second cycle, 20% (5/24 patients) in the third cycle and 33% (3/9 patients) in the fourth cycle. In seven episodes the patients had positive culture of C. difficile during the first or second day of neutropenia, whereas in 7 episodes the patients had positive cultures later during the neutropenic period.
Two episodes of C. difficile diarrhoea were associated with bacteraemia with other pathogens. During 90 cycles a total of 14 bacteraemia episodes were observed. The frequency of C. difficile in bacteraemic patients (2/14 = 14%) was not statistically significant from C. difficile in non-bacteraemic patients (12/76 = 16%), P> 0.05, Chi-square test. In seven episodes the isolation of C. difficile from faecal specimens was done on the same day as emperic treatment with cefotaxime was initiated, whereas in seven episodes antibacterial chemotherapy had been administered before C. dificdile-associated diarrhoea was diagnosed. Three cases were treated with metronidazole, six cases with oral vancomycin, whereas no treatment against C. difficile was given in the remaining five eposides. In all patients the diarrhoea disappeared.
'." Macmillan Press Ltd., 1992 Br. J. Cancer (I 992), 66, 666 667 Discussion The contribution of Clostridium difficile as a cause of diarrhoea in patients with malignant diseases as reported by others (Cudmore et al., 1982; Morris et al., 1984; Miller & Koornhof, 1984; Rampling et al., 1985; Heard et al., 1988) was confirmed by the present study. However, most reports have dealt with description of single patients (Cudmore et al., 1982; Miller & Koornhof, 1984; Rampling et al., 1985; Fainstein et al., 1981) , and only few studies have produced estimation of the incidence/prevalence of this infection in a prospectively manner (Morris et al., 1984; Heard et al., 1988) . Acute leukaemias were identified as increasing the risk of infection (Morris et al., 1984; Heard et al., 1988) , whereas no data are available for patients with solid tumours.
The high incidence of C. difficile isolation in our patients with treatment associated diarrhoea could suggest a nosocomial transmission of infection, and it is difficult to exclude this explanation as long as an efficient typing system of single isolates is not available. However, the cases were evenly distributed throughout the study period excluding any major role of nosocomial transmission. The toxin production is important in the pathogenesis of C. difficile infection, and many of the systemic symptoms may be related to absorption of the toxin. One of these manifestations may be pyrexia (Cudmore et al., 1982; Miller & Koornhof, 1984 ) and it appears to be justified to consider C. difficile in the evaluation of fever of unknown origin in the immunocompromised patient.
Many cytotoxic agents induce gastrointestinal mucosal damage. It is possible that infection with toxin producing C. difficile causes further mucosal damage, giving rise to the possibility of development of bacteraemia with other species of the gut flora. In patients with acute leukaemias Rampling et al. (1985) observed an association of bacteraemia with C. difficile diarrhoea, which was not found in our patients. This may relate to the different cytotoxic drugs used, as primarly antimetabolites have been connected with gastrointestinal toxicity, while the role of cisplatin, etoposide and bleomycin have been investigated less intensively. In one study of lung cancer patients the combination of standard-dose cisplatin and etoposide caused several diarrhoea in 8% of the patients compared to 0% of patients treated with etoposide and ifosfamide (Wolf et al., 1987) .
It is well established that prior exposure to antibacterial chemotherapy is associated with increased risk of C. difficile diarrhoea (Bartlet, 1979) . In the present study seven eposides with C. difficile occurred on the same day as start of empiric cefotaxime for fever in patients with neutropenia, which makes it unlikely that this could be causally related. In the seven other episodes it was difficult to distinguish between cytotoxic or antibacterial therapy as the initiating factor, but it should be noted that cytotoxic drugs by themselves have been suggested as precipitating C. difficile diarrhoea (Cudmore et al., 1982; Miller & Koornhof, 1984; Fainstein et al., 1981) .
In conclusion, clinical important episodes of diarrhoea are found in many patients given intensive cytotoxic chemotherapy for advanced cancer, and in a high proportion of these cases C. difficile could be isolated from faecal specimens. As C. difficile infection may aggravate the clinical condition and possibly dispose to bacteraemia in these patients, the demonstration of C. difficile should be sought for and appropriate treatment initiated when isolated.
